[Experience with the therapeutic use of grandaxin in neuroses].
The use of the drug grandaxin (made in Hungary) has demonstrated its high activity in the treatment of psychopathological disturbances of neurotic origin. Its administration is preferable when vegetative and hyposthenic disturbances are prevalent in the neurosis clinical picture. At the same time it alleviates the intensity of phobic and senestho-hypochondriacal experiences, however, its administration as the sole means for eliminating these disturbances seems undesirable. Neither can grandaxin be the drug of choice in controlling anxious and agrypnic disturbances. Psychogenic somatic syndromes have also appeared to be insensitive to the treatment with this drug. The side-effects produced by grandaxin are mild. The most persistent are nausea and headaches which develop in patients receiving high doses and subside in most cases spontaneously on reduction of the latter. No complications were noted.
D000328:Adult; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy; D005260:Female; D006801:Humans; D006998:Hypochondriasis / Q000188:drug therapy; D009440:Neurasthenia / Q000188:drug therapy; D009497:Neurotic Disorders / Q000188:drug therapy*; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy
D014151:Anti-Anxiety Agents; D001569:Benzodiazepines; C012582:tofisopam
Opyt lechebnogo primeneniia grandaksina pri nevrozakh.